Intermittent BAY1082439 treatment triggers tumor-specific CD8+ T cell activation and expansion, most likely through intra-tumoral TLS, as pre-treating the Pten-null CRPC model with S1PR modulator Fingolimod to block lymphocyte egress from hematopoietic organs and lymph nodes42 cannot prevent intra-tumoral CD8+ cell activation, clonal expansion and anti-tumor immunity (Figs. 4, 6 and 8). This evidence concerns the gene CD8A and neoplasm.